Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 18/20 | 0.74 |
| ▸ | PDE4B | Q07343 | 18/20 | 0.74 |
| ▸ | PDE4A | P27815 | 4/20 | 0.74 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30084849 | 1.00 | PDE4D (0.74) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL28899604 | 0.94 | PDE4D (0.68) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL29824400 | 0.94 | PDE4D (0.68) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL2889353 | 0.94 | PDE4D (0.68) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL30084831 | 0.93 | PDE4D (0.80) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL7371319 | 0.93 | PDE4D (0.80) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL7534706 | 0.93 | PDE4D (0.80) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL30084836 | 0.93 | PDE4D (0.80) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL717213 | 0.90 | PDE4D (0.66) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL2889262 | 0.90 | PDE4B (0.74) | PDE4DPDE4BPDE4APDE4CABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240316015-A1 | COMPOSITION AND METHOD FOR TREATING TUMORS | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2024-09-26 | — | — | US | disclosed |
| EP-4282413-A1 | COMPOSITION AND METHOD FOR TREATING TUMORS | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-11-29 | — | — | EP | disclosed |
| CN-116963773-A | Compositions and methods for treating tumors | 浙江养生堂天然药物研究所有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-115397411-A | Pharmaceutical combination and use thereof | 浙江养生堂天然药物研究所有限公司 | 2022-11-25 | — | — | CN | disclosed |
| WO-2022156727-A1 | COMPOSITION AND METHOD FOR TREATING TUMORS | 浙江养生堂天然药物研究所有限公司 | 2022-07-28 | — | — | WO | disclosed |
| WO-2021213455-A1 | DRUG COMBINATION AND USE THEREOF | 浙江养生堂天然药物研究所有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
| CN-103304475-A | Benzoic amide compound as well as preparation method and application thereof | HUNAN QIANJIN XIANGJIANG PHARM CO LTD | 2013-09-18 | — | — | CN | disclosed |
| US-7776893-B2 | Use of PDE4 inhibitors for the treatment of diabetes mellitus | NYCOMED GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| WO-2004047817-A1 | PDE4 AND PDE3/4 INHIBITORS FOR USE IN THE TREATMENT OF CACHEXIA | ALTANA PHARMA AG (DE) | 2004-06-10 | — | — | WO | disclosed |
| WO-2003024488-A2 | COMBINATION OF A PDE INHIBITOR AND A LEUKOTRIENE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | disclosed |
| EP-0706513-B1 | FLUOROALKOXY-SUBSTITUTED BENZAMIDES AND THEIR USE AS CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS | BYK GULDEN LOMBERG CHEM FAB (DE) | 2002-05-15 | — | — | EP | disclosed |
| US-5712298-A | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-01-27 | — | — | US | disclosed |
| EP-0706513-A1 | FLUOROALKOXY-SUBSTITUTED BENZAMIDES AND THEIR USE AS CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995001338-A1 | FLUOROALKOXY-SUBSTITUTED BENZAMIDES AND THEIR USE AS CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1995-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316015-A1 | COMPOSITION AND METHOD FOR TREATING TUMORS | PDE4B, PDE4A, PDE4C | PDE4D 4/4885PDE4B 1/4885PDE4A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.